www.imdconline.com

The very favorable metastatic Renal Cell Carcinoma (mRCC) risk group: data from the International Metastatic RCC Database Consortium (IMDC).

Schmidt A, Xie W, Gan C, Wells C, Dudani S, Donskov F, Porta C, Suarez C, Szabados B, Wood L, Morales J, Tran B, Bjarnason G, Yuasa T, Beuselinck B, Hansen A, Agarwal N, Bakouny Z, Heng DYC, and Choueiri TK.

Abstract ID: 339

PRESENTED AT: Genitourinary Cancers Symposium

Slides are the property of the author, permission required for reuse.

Dana-Farber Cancer Institute

#GU21

Background



1. Heng et al. *Lancet Oncol.* 2013

Slides are the property of the author, permission required for reuse.

Study Design

Training set:
3 risk factors for OS
HR: 1.4~1.5; p-values<0.05

Risk Factor	1	0
Primary diagnosis to systemic therapy	< 3 yr	≥ 3 yr
Karnofsky Performance Status	80%	> 80%
Presence of brain, liver or bone metastasis	Yes	No
0 risk factors = very favorable risk ≥1 risk factor = favorable risk		



Very Favorable: 0 risk factors (29%)
Favorable: ≥ 1 risk factors (71%)

Slides are the property of the author, permission required for reuse.

Results

Overall Survival



	Very Favorable (n=454)	Favorable (n=1091)	Hazard ratio (95% CI) p-value
Median OS, months (95% CI)	64.8 (58.8 - 70.8)	45.6 (42.0 - 50.4)	1.84 (1.56 - 2.20) <0.001
Median time to treatment failure, months (95% CI)	16.3 (14.8 - 18.2)	12.0 (11.2 - 12.9)	1.31 (1.16 - 1.48) <0.001

Slides are the property of the author, permission required for reuse.

Conclusions

Readily available clinical factors can identify a very-favorable risk cohort of mRCC patients

Results require validation in an external data set

Correlation to underling biology is ongoing

www.imdconline.com

Thank you to my co-authors and IMDC

@dr_aschmidt

Slides are the property of the author, permission required for reuse.